New drug combo aims to stop deadly esophageal Cancer's return
NCT ID NCT07177794
Summary
This study is for people with a type of esophageal cancer who have just finished standard chemoradiation treatment. It tests whether taking two drugs (toripalimab and capecitabine) for a longer period as 'maintenance therapy' can help keep the cancer from growing back and help patients live longer. The goal is to see if this extra treatment is safe and more effective than the current standard, which has a high chance of the cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.